T-cell vaccine
Showing 1 - 25 of >10,000
COVID-19 Trial in Johannesburg (AAHI-SC2 Vaccine, AAHI-SC3 Vaccine, EUA or approved vaccine)
Recruiting
- COVID-19
- AAHI-SC2 Vaccine
- +2 more
-
Johannesburg, South AfricaWits Vida
Jan 4, 2023
HER2-positive Breast Cancer Trial in Tampa (Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab)
Recruiting
- HER2-positive Breast Cancer
- Dendritic Cell (DC1) Vaccine
- +3 more
-
Tampa, FloridaMoffitt Cancer Center
Dec 28, 2022
High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin
Not yet recruiting
- High Grade B-Cell Non-Hodgkin's Lymphoma
- +3 more
- Anti-CD19-CAR CMV-specific T-lymphocytes
- +9 more
-
Duarte, CaliforniaCity of Hope Medical Center
Apr 5, 2023
Idiopathic CD4 T Cell Lymphocytopenia Trial run by the NIAID (Gardasil 9)
Recruiting
- Idiopathic CD4 T Cell Lymphocytopenia
- Gardasil 9
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 10, 2023
Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,
Not yet recruiting
- Kidney Transplant
- +2 more
- Cyclophosphamide
- +3 more
-
Boston, Massachusetts
- +2 more
Sep 20, 2023
Coronavirus, SARS-CoV-2 Infection, COVID-19 Trial in Imus, Makati City (PepGNP-COVID19 (One vaccination), Water for injection
Not yet recruiting
- Coronavirus
- +2 more
- PepGNP-COVID19 (One vaccination)
- +3 more
-
Imus, Cavite, Philippines
- +1 more
Nov 30, 2022
Refractory Leukemia, Relapsed Leukemia, Acute Myelogenous Leukemia Trial in Miami (STING-Dependent Activators (STAVs) Loaded
Not yet recruiting
- Refractory Leukemia
- +4 more
- STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells
- Dendritic Cell Vaccine
-
Miami, FloridaUniversity of Miami
Jan 23, 2023
COVID Vaccine Immunity in Kidney Transplant Recipients
Withdrawn
- End Stage Renal Disease
- Kidney Transplant; Complications
- Coronavirus (COVID-19) SARS-CoV-2 inSIGHTâ„¢ T Cell Immunity Test
- (no location specified)
Oct 25, 2022
Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL) Trial in
Recruiting
- Diffuse Large-Cell Lymphoma
- +3 more
- Pneumococcal conjugate vaccine (PCV13)
- CD19 targeted CAR T Cell Therapy
-
Tampa, FloridaMoffitt Cancer Center
May 31, 2022
B-Cell Non-Hodgkin Lymphoma, DLBCL, Mantle Cell Lymphoma Trial in Duarte (Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous
Not yet recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Anti-CD19-CAR CMV-specific T-lymphocytes
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 28, 2022
Plasma Cell Myeloma Trial in Omaha (drug, procedure, biological)
Active, not recruiting
- Plasma Cell Myeloma
- Melphalan
- +4 more
-
Omaha, NebraskaUniversity of Nebraska Medical Center
Nov 21, 2022
T-Cell Acute Lymphoblastic Leukemia Trial in Shenzhen (Antigen-specific T cells CAR-T/CTL and DCvac)
Recruiting
- T-Cell Acute Lymphoblastic Leukemia
- Antigen-specific T cells CAR-T/CTL and DCvac
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Mar 14, 2022
Non Small Cell Lung Cancer Trial in Leiden, Rotterdam (TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51))
Recruiting
- Non Small Cell Lung Cancer
- TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)
-
Leiden, Zuid-Holland, Netherlands
- +1 more
Jun 1, 2023
Flu Vaccine Trial in Nashville (Fluzone-High Dose Quadrivalent, Fluad, Flublock)
Completed
- Flu Vaccine
- Fluzone-High Dose Quadrivalent
- +2 more
-
Nashville, TennesseeVanderbilt University Medical Center
Jun 16, 2022
Prostate Specific Antigens, Prostate Tumors Trial run by the National Cancer Institute (NCI) (TARP peptide vaccine, TARP
Completed
- Prostate Specific Antigens
- Prostate Neoplasms
- T-cell receptor alternate reading frame protein (TARP) peptide vaccine
- T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 15, 2022
Dengue Trial in Lausanne (LD vehicle-GNP, LD PepGNP-Dengue, HD vehicle-GNP)
Completed
- Dengue
- LD vehicle-GNP
- +3 more
-
Lausanne, Vaud, SwitzerlandCenter for Primary Care and Public Health, (Unisante)
Nov 28, 2022
FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at
Recruiting
- Monkeypox
-
Antwerp, BelgiumInstitute of Tropical Medicine
May 19, 2023
Epithelial Ovarian Cancer, Ovarian Carcinoma Trial in Nijmegen (XP-DC vaccinations)
Not yet recruiting
- Epithelial Ovarian Cancer
- Ovarian Carcinoma
- XP-DC vaccinations
-
Nijmegen, Gelderland, NetherlandsRadboud University Medical Center
Mar 6, 2023
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Rochester (procedure, biological,
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +9 more
- Cryosurgery
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 9, 2022
Coronavirus, SARS-CoV-2 Infection, COVID-19 Trial in Lausanne (LD Vehicle-GNP, LD PepGNP-SARSCoV2, HD Vehicle-GNP)
Completed
- Coronavirus
- +2 more
- LD Vehicle-GNP
- +3 more
-
Lausanne, Vaud, SwitzerlandCenter for Primary Care and Public Health (Unisante)
Nov 28, 2022
B-Cell Acute Lymphoblastic Leukemia Trial in Shenzhen (Antigen-specific T cells CART/CTL and DCvac)
Recruiting
- B-Cell Acute Lymphoblastic Leukemia
- Antigen-specific T cells CART/CTL and DCvac
-
Shenzhen, Guangdong, ChinaShenzhen Geno-Immune Medical Institute
Mar 7, 2022
Covid19 Trial (hAd5-S-Fusion+N-ETSD vaccine)
Withdrawn
- Covid19
- hAd5-S-Fusion+N-ETSD vaccine
- (no location specified)
Dec 14, 2021
COVID-19, Infection Viral, Infections Trial in Bergen, Oslo (VB10.2129, VB10.2210)
Active, not recruiting
- COVID-19
- +2 more
- VB10.2129
- VB10.2210
-
Bergen, Norway
- +1 more
Jan 6, 2023
Covid19 Trial (hAd5-S-Fusion+N-ETSD vaccine)
Withdrawn
- Covid19
- hAd5-S-Fusion+N-ETSD vaccine
- (no location specified)
Dec 14, 2021
HIV-1-infection Trial in Brazil, United States (ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3)
Not yet recruiting
- HIV-1-infection
- ChAdOx1.tHIVconsv1
- +7 more
-
San Diego, California
- +11 more
Oct 4, 2023